Compare Viatris Inc (VTRS) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Wix.Com Ltd — how do they compare? Viatris Inc trades at $16.18 (market cap $18.69B), while Wix.Com Ltd trades at $68.75 (market cap $2.79B). The key difference: Viatris Inc is far larger — about 6.7× Wix.Com Ltd's market cap, and Viatris Inc pays a 2.95% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| VTRS | WIX | |
|---|---|---|
Market Cap | $18.69B | $2.79B |
Sector | Health | Technology |
52-Week High | $17.86 | $184.24 |
52-Week Low | $9.49 | $40.43 |
Enterprise Value | $30.80B | $3.87B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
WIX trades at $66.60, up 6.69% today, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75. Revenue grew to $1.99B in 2025, though net income margin remains negative at -8.19%. Recent news includes the launch of Symphony by Wix, an AI system for SMBs, but the stock faces multiple class-action lawsuits following a 27% drop after Q1 2026 earnings missed expectations.
The outlook is mixed: strong revenue growth and analyst buy ratings suggest upside, but legal risks and volatile earnings pose significant challenges. Investors should weigh the high P/E of 62.84 against competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
